
Tuesday, September 28, 2021 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST In the last few years, the issuance of the ISO 10993-18:2020 medical device guidance and several high-profile publications and round-robin studies have resulted in the FDA increasing scrutiny of E&L analyses for both drugs and devices. Join our panel of industry experts to discuss these changes and to learn the direction E&L may take into the future.






